Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis

BACKGROUND: Topical Janus kinase (JAK) inhibitors are being developed for the treatment of mild to moderate atopic dermatitis. However, comparative evidence on their safety profiles is still limited. AIM: This study aimed to compare the relative safety of topic JAK inhibitors in patients with atopic...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Carlos, Penedones, Ana, Mendes, Diogo, Batel Marques, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366300/
https://www.ncbi.nlm.nih.gov/pubmed/37074513
http://dx.doi.org/10.1007/s11096-023-01569-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366300/
https://www.ncbi.nlm.nih.gov/pubmed/37074513
http://dx.doi.org/10.1007/s11096-023-01569-x

Ejemplares similares